Asher Bio 是一家生物技术公司，专注于开发疗法，以精确地利用特定的免疫细胞来对抗癌症、慢性病毒感染和自身免疫性疾病。我们利用我们专有的顺式靶向平台开发疗法，通过选择性激活具有经过验证的抗病功能的特定免疫细胞类型来克服其他基于免疫的治疗的局限性。我们的候选者具有与修饰的免疫调节蛋白（例如细胞因子）相关的抗体。我们的候选设计旨在使我们的候选者能够选择性地激活所需的免疫细胞，而不是其他导致毒性或免疫抑制的细胞。 Asher Bio 由 Ivana Djuretic 和 Andy Yeung 在 Third Rock Ventures 的支持下创立，位于旧金山南部。欲了解更多信息，请访问 www.asherbio.com 并在 Twitter @AsherBio 和 LinkedIn 上关注我们。
联系人
Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022
Shows potential for CD8+ T cell targeted immunotherapy for chronic viral infections
October 21, 2022 09:00 AM Eastern Daylight Time
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infections and autoimmune disorders, today announced that it will present the first preclinical data for AB359, its CD8-targeted interleukin-2 (IL-2) immunotherapy for the treatment of chronic viral infections, at the American Association for the Study of Liver Disease (AASLD) 2022 Annual Meeting, being held in Washington, DC, on November 4-8, 2022. The preclinical data indicates that selective activation of the IL-2 pathway in CD8+ T cells drives antiviral activity in a model of hepatitis B virus (HBV) and supports the development of AB359 as a potentially more tolerable and more active IL‑2-based therapy for the treatment of chronic HBV.
Details of the poster presentation are as follows:
Title: Selective activation of the IL-2 pathway in CD8+ T cells drives antiviral activity in a hepatitis B virus (HBV) model
Session Date and Time: November 4, 2022, 12:00-1:00 p.m. ET
Location: Poster Hall
Abstract Number: 1198
About Asher Bio
Asher Bio is a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infections and autoimmune disorders. We utilize our proprietary cis-targeting platform to develop therapies engineered to overcome limitations of other immune-based treatments by selectively activating specific immune cell types with validated disease fighting functionality. Our candidates feature an antibody connected to a modified immunomodulatory protein, such as a cytokine. Our candidate design is intended to enable our candidates to selectively activate the desired immune cells and not other cells that contribute to toxicity or immune suppression. Asher Bio was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and is located in South San Francisco. For more information, please visit www.asherbio.com and follow us on Twitter @AsherBio and on LinkedIn.
Contacts
Media Contact
Kathryn Morris, The Yates Network
914-204-6412 [email protected]